Search Results
Your search for ,aLl matches 18304 pages
Showing 16301 - 16350ASTRO Guidelines on Radiotherapy in Locally Advanced NSCLC: A Good Place to Start
ASCO’s endorsement of the American Society for Radiation Oncology (ASTRO) guidelines on the role of radiotherapy in locally advanced non–small cell lung cancer (NSCLC) is an important summary of the best evidence on the appropriate role and techniques for radiotherapy in this disease.1 These...
Collaborating Toward a Cure
We’ve seen how dramatically patients’ lives can change when they are matched with the right treatment at the right time in their disease course. Although this is still an exception and not the rule, we believe collaborative research approaches will make this kind of precision medicine a reality for ...
Collaboration Between Surgeons and Medical Oncologists Improves Outcomes for Patients With Stage III Colon Cancer
Collaboration between surgeons and medical oncologists “is associated with lower mortality without increased cost among patients with stage III colon cancer,” according to a study by Tanvir Hussain, MD, MSc, and colleagues from Johns Hopkins University School of Medicine, Baltimore, and the...
Medicare to Reimburse Doctors for End-of-Life Counseling
In a breakthrough proposal announced on July 8, the Centers for Medicare & Medicaid Services (CMS) plans to reimburse physicians for end-of-life counseling, a move that the oncology community has long been lobbying for. Arriving just as the presidential election cycle begins to heat up, the CMS ...
Mount Sinai Honors James F. Holland, MD, FASCO, on the Occasion of His 90th Birthday
On May 14, 2015, over 160 colleagues, family members, friends, and patients of James F. Holland, MD, FASCO, gathered in the Goldwurm Auditorium in the Icahn School of Medicine at Mount Sinai Hospital in New York to honor Dr. Holland for the contributions he has made during his remarkable career in ...
Daratumumab Expanded Access Program Open to Eligible U.S. Patients With Heavily Pretreated Multiple Myeloma
Janssen Biotech, Inc, announced the opening of a daratumumab expanded access program for eligible patients in the United States. Daratumumab is an investigational human anti-CD38 monoclonal antibody being evaluated in clinical trials as a treatment for patients with multiple myeloma. The...
The Importance of Including Adolescents and Young Adults With Cancer in Their Advance Care Planning
Three years ago, a study of adolescents and young adults aged 16 to 28 with metastatic or recurrent cancer or HIV/AIDS compared the usefulness of two previously developed advance care planning guides—one prepared specifically for adolescents and young adults and one specifically for adults. The...
Charles Rubin, MD, Pediatric Cancer Specialist, Dies at 62
Charles M. Rubin, MD, Associate Professor of Pediatrics at the University of Chicago Medicine, a highly respected specialist in the care of children with cancer, died on July 17. He was 62. An authority on all aspects of pediatric cancers, Dr. Rubin had a particular interest in brain tumors and...
A Lasting Legacy
When Emil J Freireich, MD, retires from the University of Texas MD Anderson Cancer Center on September 1, he will have spent 50 years at the institution and a total of 60 years in the pursuit of curing childhood leukemia as well as other cancers and in the educational development of young...
Translational Research: Dogs and Humans Nearly Interchangeable in the Laboratory
“Between animal and human medicine there is no dividing line—nor should there be. The object is different but the experience obtained constitutes the basis of all medicine.” — Rudolf Virchow (1821–1902) Everyone has seen photographs of people who look like their dogs: the young woman with long...
Community Oncologist Stephen Grubbs, MD, to Lead ASCO’s New Clinical Affairs Department
Stephen S. Grubbs, MD, a community oncologist and managing partner at Medical Oncology Hematology Consultants, PA, in Newark, Delaware, has been named the Senior Director of ASCO’s new Clinical Affairs department. Dr. Grubbs is a longtime ASCO member and volunteer and the Principal Investigator of...
Summer Travel: Help Your Patients Understand Why Getting Medical Clearance is Important
Direct your patients to www.cancer.net/blog to get important information on traveling with cancer, including getting medical clearance before they book their flight. This information includes questions to ask the doctor, how to get permission from the airline to fly, and information on packing...
Register for the Community Research Forum 2015 Annual Meeting
Registration is open for the Community Research Forum (CRF) 2015 Annual Meeting, which will be held September 20–21, at ASCO Headquarters in Alexandria, Virginia. Join fellow physician investigators and research staff from all types of community-based research sites and programs to discuss barriers ...
Disease Prevention, Practice Issues Put ASCO Center Stage at AMA House of Delegates Meeting
ASCO represented the oncology community at the American Medical Association’s (AMA) Annual House of Delegates (HOD) Meeting, held June 6–10 in Chicago. While AMA’s chief policy-making body worked to shape its priorities and initiatives, ASCO delegates and alternates represented the cancer care...
2015–2016 ASCO President Julie M. Vose, MD, MBA, FASCO: Leading During a Year of Historic Changes
Julie M. Vose, MD, MBA, FASCO, began her term as the 2015–2016 President of ASCO at the 2015 Annual Meeting on June 1, 2015. Dr. Vose, a leading expert in the treatment of patients with lymphoma, is the current Neumann M. and Mildred E. Harris Professorial Chair and Chief of the Oncology/Hematology ...
Collective Wisdom: Patient-Centered Care and Research
In 1964, when the first seven physicians who founded ASCO met, I doubt they imagined what a successful Society they were forming. At that time, cancer treatments were just beginning to have some early successes with a few cytotoxic therapies, new radiation modalities, and improved surgical...
Blame
The following essay by Karen J. Krag, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. It is easier ...
The Human Heart: Tales of Science and Mystery
BOOKMARK Title: The Man Who Touched His Own Heart: True Tales of Science, Surgery, and Mystery Author: Rob Dunn Publisher: Little, Brown and Company Publication date: February 3, 2015 Price: $27.00; hardcover, 384 pages No part of the human anatomy has been as mythologized, analogized, and...
An Oncologist’s Memoir
BOOKMARK Title: Megalies: A Memoir Author: Lodovico Balducci, MD Publisher: Resource Publications Publication date: February 28, 2014 Price: $33.00; hardcover, 304 pages Reading a good book produces various sensory responses; a skilled author exerts his or her narrative power on each page,...
Using Gene Analytics to Identify Patients at Risk for Treatment Toxicity
Genomic applications are now an accepted part of oncologic science and practice. Differences in gene expression have been used to understand and predict tumor behaviors and response to treatment. And now it seems likely that genomics may also play a pivotal role in guiding treatment preferences by...
St. Jude to Receive $12 Million in Grants From NIH
Investigators at St. Jude Children’s Research Hospital have received grants totaling more than $12 million from the National Institutes of Health’s (NIH) Pharmacogenomics Research Network (PGRN) for a new Center for Precision Medicine in Leukemia and for the Clinical Pharmacogenetics Implementation ...
Past President of ASCO Takes on New Role at Memorial Sloan Kettering Cancer Center to Improve Patient Care and Public Health
In June, Memorial Sloan Kettering Cancer Center (Memorial) in New York announced it had appointed Clifford A. Hudis, MD, FACP, Chief of Breast Medicine Service, to a newly created position of Vice President for Government Relations and Chief Advocacy Officer. In addition to his new role, Dr. Hudis ...
No Survival Benefit for Eribulin vs Capecitabine in Advanced Breast Cancer
Eribulin (Halaven) currently is indicated in the United States for treatment of patients with metastatic breast cancer who previously received at least two chemotherapy regimens for metastatic disease and an anthracycline and a taxane in either the adjuvant or metastatic setting. Its approval was...
ODAC Discussion ‘Constructive’ About Necitumumab for Squamous NSCLC
The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) favored the approval of necitumumab in combination with gemcitabine and cisplatin for use in first-line treatment of patients with locally advanced or metastatic squamous non–small cell lung cancer (NSCLC). In...
Magnetic Resonance Imaging/Ultrasound Fusion: A Promising Technology for Image-Guided Prostate Biopsy
An elegant study by Siddiqui et al1—reviewed in this issue of The ASCO Post—offers compelling evidence for the diagnostic utility of “targeted” prostate biopsy using multiparametric magnetic resonance imaging (MRI) data fused with ultrasound images. The technique involves first performing a...
Magnetic Resonance Imaging/Ultrasound Fusion–Guided Biopsy Improves Detection of High-Risk Prostate Cancer
In a study reported in JAMA, M. Minhaj Siddiqui, MD, currently of the University of Maryland School of Medicine, and colleagues found that targeted magnetic resonance imaging (MRI)/ultrasound fusion–guided prostate biopsy increased diagnosis of high-risk prostate cancer and reduced detection of...
The Value Proposition in Oncology: ASCO Session Weighs Points of View
The value proposition in health care is often represented with the following equation: Value = Outcomes/Cost. The simplicity of this equation, however, belies the complexity of its parts, which are the contributions of multiple stakeholders with unique perspectives. A session presented at the 2015...
ESMO’s Magnitude of Clinical Benefit Scale Brings Unbiased Perspective to Cancer Drugs’ Worth
An anticancer therapy may be hailed as a breakthrough in some corners, whereas its value may be hotly contested in others. In an effort to bring clear, unbiased perspective to new expensive therapies, the European Society for Medical Oncology (ESMO) has created a valuable tool for oncologists,...
Glioblastoma: Novel Immunotherapy Approaches Generate Responses and Excitement
Checkpoint inhibitors were major attention grabbers at the 2015 ASCO Annual Meeting, but studies suggested there are other encouraging means of harnessing the immune system in the treatment of glioblastoma. EGFRvIII-Targeted Vaccine David A. Reardon, MD, Clinical Director of the Center for...
Value: What Do We Mean, Who Should Decide?
Oscar Wilde famously defined a cynic as “a man who knows the price of everything and the value of nothing.” I do not think that oncologists need to be as cynical as this, but it was very appropriate that a major theme of this year’s ASCO Annual Meeting was the concept of “value.” It is clear that...
Bevacizumab More Cost-Effective Than Cetuximab in Metastatic Colorectal Cancer
The landmark CALGB/SWOG 80405 trial concluded that bevacizumab (Avastin) and cetuximab (Erbitux) provide comparable benefit in the treatment of metastatic colorectal cancer. However, in terms of cost, bevacizumab was recently declared the winner. In an economic analysis presented at the 2015 ASCO...
Collaboration Between Surgeons and Medical Oncologists Improves Outcomes for Patients With Stage III Colon Cancer
Collaboration between surgeons and medical oncologists “is associated with lower mortality without increased cost among patients with stage III colon cancer,” according to a study by Tanvir Hussain, MD, MSc, and colleagues from Johns Hopkins University School of Medicine, Baltimore, and the...
Expect Questions About Increased Risk of Melanoma From Consuming Grapefruits and Orange Juice
Could too much citrus cause skin cancer?” was the lead-in of an NBC News item about a study linking consumption of grapefruits and oranges to an increased risk of melanoma.1 “Citrus consumption and skin cancer: How real is the link?” was the question posed by a headline in The Washington Post.2...
Public Urged Not to Overreact to Study Finding Link Between Citrus Fruits and Melanoma Risk
A study finding a link between citrus consumption and increased risk of melanoma1 may provide food for thought about the findings and implications as well as whet the appetite for more evidence, but according to several experts commenting on the study, it does not mean you should stop eating citrus ...
ACCC Launches Immuno-Oncology Program for Community‐Based Cancer Care Providers
The Association of Community Cancer Centers (ACCC) has launched the Institute for Clinical Immuno-Oncology (ICLIO), a first-of-its-kind initiative aimed to facilitate the rapid adoption of immuno-oncology in the community cancer setting. To help with the rapid uptake of immuno-oncology at the...
Microangiopathic Hemolytic Anemia and Thrombocytopenia: Answers From Hematology Expert Review Questions
Question 1: What is the best first step in management of this patient? Correct Answer: C. Start plasma exchange. Expert Perspective Although distinguishing among thrombotic thrombocytopenic purpura, typical hemolytic uremic syndrome, and atypical hemolytic uremic syndrome (see Table 1 in the...
Be a Voice in The Campaign to Conquer Cancer
We’ll provide the resources—you provide the voice. The Campaign to Conquer Cancer is raising $150 million to support a world free from the fear of cancer. Our potential to raise money increases with every new person who learns about our work. We need the most trusted leaders in the oncology...
Strengthening the Doctor-Patient Relationship: An Interview With Lidia Schapira, MD, FASCO
Earlier this summer, Lidia Schapira, MD, FASCO, a medical oncologist at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School, was named Editor-in-Chief of Cancer.Net, ASCO’s patient information website. Prior to taking on this role, Dr....
Obesity and Cancer Bundle: Oncology Provider Guides and Patient Booklets
Many cancer care providers struggle with addressing the topics of weight loss and weight management with their patients. Obesity and Cancer: A Guide for Oncology Providers is a tool that will help oncology providers integrate strategies for weight loss into their practices by offering practical...
Conquer Cancer Foundation Donor Spotlight: Ludwig Cancer Research
Among the Conquer Cancer Foundation’s newest supporters, Ludwig Cancer Research is an international community of distinguished scientists dedicated to preventing and controlling cancer. Its emphasis on collaboration and long-term support has fostered its role as a leader in immunotherapy and other...
Physician Fee Schedule: A Closer Look
The Centers for Medicare & Medicaid Services (CMS) issued the Notice of Proposed Rulemaking for the 2016 Physician Fee Schedule on July 15. Among other changes, CMS proposes new codes and payment levels for Advance Care Planning; requests comments for future implementation of the Medicare...
New Symposium Brings Together Oncologists and Primary Care Providers to Advance Survivorship Care and Research
With two-thirds of Americans now living at least 5 years after a cancer diagnosis, there are currently 14.5 million cancer survivors living in the United States. By 2024, that number is expected to increase by nearly 25%.1 Although the growing number of survivors is a welcome sign of progress, this ...
Sonidegib in Basal Cell Carcinoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On July 24, 2015, sonidegib (Odomzo) was approved for treatment...
Johnson & Johnson Creates Independent Bioethics Panel to Evaluate Compassionate Drug Use Requests
In May 2015, Johnson & Johnson announced its partnership with New York University (NYU) School of Medicine in New York to create a first-of-its kind independent bioethics panel to review requests made to the company for compassionate use of an investigational drug and determine how the company...
Geriatric Oncology: A Geriatrician’s Perspective
“The management of older individuals, including older cancer patients, involves a wisdom developed over a lifetime, thanks to time-consuming listening and painstaking collection and interpretation of clinical details.” —Lodovico Balducci, MD It is not simple to be a geriatrician in a world of...
Clinical Trials Actively Recruiting Patients With Genitourinary Cancers
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with genitourinary cancers—prostate, bladder, uterine, and testicular. The trials are investigating genetic biomarkers of cancer; proton beam therapy; allogeneic bone marrow...
APOS Announces 2015 Award Winners at the World Congress of Psycho-Oncology
The American Psychosocial Oncology Society (APOS) honored five award winners at the 2015 World Congress of Psycho-Oncology, held from July 28–August 1 in Washington, DC. Holland Distinguished Leadership Award: Matthew J. Loscalzo, LCSW Professor Loscalzo is the Liliane Elkins Professor in...
New Molecular Classifications of Gliomas Established
Two studies reported in The New England Journal of Medicine identified new molecular classifications of glioma that capture biologic and prognostic differences. The Cancer Genome Atlas Research Network identified three prognostically significant subtypes of lower-grade glioma that were identified...
Adding Everolimus to First-Line Trastuzumab/Paclitaxel Does Not Increase Progression-Free Survival in HER2-Positive Metastatic Breast Cancer
In the phase III BOLERO-1 trial, reported in The Lancet Oncology, Sara A. Hurvitz, MD, of the University of California, Los Angeles, and colleagues found that the addition of the mTOR inhibitor everolimus (Afinitor) to trastuzumab (Herceptin)/paclitaxel did not significantly increase...
Calculating the Value of Cancer Drugs
For nearly a decade, Peter B. Bach, MD, MAPP, Director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center in New York, has been a leading voice in sounding the alarm over the escalating cost of cancer drugs and in seeking a solution to the problem. In 2012, Dr....
